» Articles » PMID: 29307588

Autoantibodies Against Podocytic UCHL1 Are Associated with Idiopathic Nephrotic Syndrome Relapses and Induce Proteinuria in Mice

Overview
Journal J Autoimmun
Date 2018 Jan 9
PMID 29307588
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Idiopathic steroid sensitive nephrotic syndrome (INS), the most frequent childhood nephropathy, is thought to be mediated by a circulating soluble factor that reversibly affects the renal protein sieving. The efficiency of rituximab therapy recently highlighted the involvement of B cells. Here we studied the involvement of a specific immunoglobulin G (IgG) in the disease. After plasma fractionation by size exclusion chromatography, a detachment of cultured podocyte was observed with one IgG-containing fraction from 47% patients in relapse, 9% of patients in remission and 0% of controls. Podocyte protein lysates were immunoprecipitated by IgG from those plasma fractions identifying a list of 41 podocyte proteins after proteomic analysis. Five podocyte targets were selected on statistical and biological criteria. Specific antibodies were tested and only anti-Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) IgG led to podocyte detachment. UCHL1 was mainly found inside the podocyte but also weakly expressed on podocyte cell surface. Incubation of either anti-UCHL1 IgG or plasma fractions with recombinant UCHL1 prevented podocyte detachment. Plasma levels of anti-UCHL1 IgG were significantly increased in relapsing INS patients compared to patients in remission and controls. Proteinuria correlated with anti-UCHL1 IgG level at various stages of the disease. Purified patient anti-UCHL1 antibodies induced proteinuria and podocyte foot effacement in mice. Altogether, these results identified UCHL1 as a target podocyte protein of autoantibodies in a set of relapsing patients and support a causative role of anti-UCHL1 autoantibodies in the development of INS.

Citing Articles

Genetic and Iatrogenic Defects in Peripheral Tolerance Associated with Anti-Nephrin Antibody-Associated Minimal Change Disease.

Jefferson J, Chen K, Hingorani S, Malik A, Tykodi S, Keller K Glomerular Dis. 2025; 5(1):74-83.

PMID: 39991196 PMC: 11845169. DOI: 10.1159/000543334.


Autoantibodies in the Pathogenesis of Podocytopathies.

Blume L, Meyer-Schwesinger C J Am Soc Nephrol. 2025; 36(3):336-338.

PMID: 39883526 PMC: 11888953. DOI: 10.1681/ASN.0000000624.


Editorial: Insights in glomerular disease.

Chang B, Koirala A, Geetha D Front Nephrol. 2024; 4:1480968.

PMID: 39726793 PMC: 11669952. DOI: 10.3389/fneph.2024.1480968.


The Pathogenesis of Nephrotic Syndrome: A Perspective from B Cells.

Zhu S, Zhang J, Gao L, Ye Q, Mao J Kidney Dis (Basel). 2024; 10(6):531-544.

PMID: 39664337 PMC: 11631018. DOI: 10.1159/000540511.


Increased levels of antibodies to synaptopodin and annexin 1 in patients with primary podocytopathies.

Chebotareva N, Charionovskaya E, Biryukova E, Vinogradov A, Alentov I, Sergeeva N Front Nephrol. 2024; 4:1471078.

PMID: 39544697 PMC: 11560892. DOI: 10.3389/fneph.2024.1471078.